This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Dandan Zhu, Zijian Zheng, Huixin Huang, Xiaojuan Chen, Shuhong Zhang, Zhuchu Chen, Ting Liu, Guangyu Xu, Ying Fu, Yongheng Chen, European Journal of Medicinal Chemistry , 2025 [link] Fibroblast growth factor receptors (FGFRs) represent promising therapeutic targets in various malignancies, yet the clinical application of FGFR covalent inhibitors has been impeded by several significant challenges, including unquantifiable target engagement, undefined off-target effects, and the emergence of drug
SUNDAY, May 25, 2025 The first day of preschool can be tough lots of new faces, unfamiliar sounds and the sudden goodbye to Mom or Dad can be overwhelming. But what if something as simple as the ceiling could make it a little easier?New res.
Based on the previously reported crystal structure of the POLRMT inhibitor IMT1B, a series of derivatives with additional hydrophobic occupancy groups were designed and synthesized using a scaffold jumping strategy. A new potent POLRMT inhibitor ( 10a ) showed potent antiproliferative activity in MOLM-13 cells that disrupted mitochondrial function and induced apoptosis.
Twenty new fluoroquinolone-azole conjugates were synthesized. The synthesized compounds were screened vs. various bacterial and mycobacterial strains. Most of the compounds showed potent antibacterial activity. Compound 35 was equipotent with ciprofloxacin vs. M. tuberculosis H37Rv. In silico and invitro study of compound 35 against DNA-gyrase enzyme were performed.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content